Literature DB >> 11578749

Absorption of water-soluble compounds with different molecular weights and.

A Yamamoto1, T Iseki, M Ochi-Sugiyama, N Okada, T Fujita, S Muranishi.   

Abstract

The absorption of water soluble compounds with different molecular weights, such as phenol red (MW 354), trypan blue (MW 960), fluorescein isothiocyanate dextrans, (MW 4400 and 9100) was studied in the lung, nasal cavity, buccal cavity, small and large intestine of rats. For all the compounds, maximal absorption was observed when administered to the lung. The rank order of absorption of each compound from various administration sites was lung>small intestine> or =nasal cavity> or =large intestine> or =buccal cavity. In addition, the relationship between logarithm absorption % of the compounds from various administration sites and logarithm molecular weights of these compounds was examined. The absorption of compounds gradually decreased with increasing molecular weight for each site of administration. Moreover, the absorption of [Asu1.7]-eel calcitonin (ECT) from these sites and the effect of 10 mM sodium glycocholate, an absorption enhancer, on its absorption were also investigated in rats. When ECT alone was administered into these sites, the lung had the best absorption site of ECT, followed by the nasal cavity, the large intestine, the small intestine and the buccal cavity. Therefore, the absorption of ECT was also dependent on the administration site, although the rank order of absorption % of ECT was different from the other compounds. Sodium glycocholate (NaGC) remarkably increased ECT absorption from the small intestine, while we found marginal increase in its absorption from the lung even in the presence of NaGC. These findings provided useful fundamental information that might aid in the selection of administration routes for drugs of differing molecular weights including peptide drugs as far as the degree of drug absorption is concerned.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578749     DOI: 10.1016/s0168-3659(01)00454-0

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  5 in total

Review 1.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.

Authors:  D S Quintana; A J Guastella; L T Westlye; O A Andreassen
Journal:  Mol Psychiatry       Date:  2015-11-10       Impact factor: 15.992

2.  Clinical study shows improved absorption of desmopressin with novel formulation.

Authors:  Nelly Fransén; Susanne Bredenberg; Erik Björk
Journal:  Pharm Res       Date:  2009-03-19       Impact factor: 4.200

Review 3.  Enhancing the buccal mucosal delivery of peptide and protein therapeutics.

Authors:  Thiago Caon; Liang Jin; Cláudia M O Simões; Raymond S Norton; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-08-29       Impact factor: 4.200

4.  Effect of administration method, animal weight and age on the intranasal delivery of drugs to the brain.

Authors:  Jishnu K S Krishnan; Peethambaran Arun; Bhadra Chembukave; Abhilash P Appu; Nivetha Vijayakumar; John R Moffett; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  J Neurosci Methods       Date:  2017-05-10       Impact factor: 2.390

5.  Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA.

Authors:  Mireya L Borrajo; María José Alonso
Journal:  Drug Deliv Transl Res       Date:  2021-11-03       Impact factor: 4.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.